Centre Léon Bérard, Lyon: Cancer Care and Clinical Trials

Founded in 1923, Centre Léon Bérard developed into a specialist institution dedicated to cancer care, research and education. It is a private, non-profit cancer centre within France’s healthcare system, rather than a general hospital covering all medical specialities.

The centre belongs to UNICANCER, the network of French comprehensive cancer centres. It is a substantial specialist institution bringing together diagnostic services, medical oncology, surgery, radiation oncology and research. Bed numbers and workforce totals are not given here because they change and do not, by themselves, establish suitability for an individual patient.

The centre is known for sarcoma expertise, care for common and rare cancers, and links between research and clinical practice. Its relationship with the Cancer Research Center of Lyon supports research including immunotherapy. These activities may inform specialist assessment and study opportunities, but they do not mean that every experimental treatment is available in routine care.

Sarcoma is a particular area of expertise. Centre Léon Bérard has a French national reference role within NETSARC, the sarcoma reference network. Sarcomas comprise many different diseases affecting soft tissues or bone, and expert pathology review can be important before treatment decisions. Patients should ask whether their diagnosis needs specialist confirmation and which team would assess their particular subtype.

Breast cancer and lung cancer are also established areas of care, alongside programmes addressing rare cancers. Assessment may involve imaging, pathology and molecular testing to distinguish subtypes and guide treatment. For rare cancers, the relevant expertise depends on the precise diagnosis: a broad rare-cancer programme does not imply that every uncommon tumour has the same treatment options or an available trial.

Surgery and radiation therapy are available as part of multidisciplinary cancer care. Their role depends on the tumour’s location, stage, operability and the patient’s general health. Treatment may aim to cure disease, reduce recurrence risk or relieve symptoms. Patients should ask which approach is proposed, why it is preferred and whether comparable care is available closer to home.

Drug treatment includes immunotherapy where indicated, alongside other systemic treatments chosen for the cancer type and clinical situation. Immunotherapy is not suitable for every cancer and can cause significant immune-related side effects. Previous treatment, autoimmune conditions, organ function and other health factors may affect eligibility and monitoring requirements.

Precision oncology uses tumour characteristics, including molecular findings where relevant, to help guide treatment selection. Testing does not always identify an actionable alteration, and an identified alteration does not guarantee access to an effective drug. Some options may be standard care, while others are available only through research or specific access arrangements. Ask the team to distinguish these categories clearly.

The centre has a substantial clinical research programme, with around 250 active oncology clinical trials reported as an indicative figure. The portfolio changes over time, and active studies may include trials that are no longer recruiting but continue to follow participants. Its phase I unit conducts early-phase research, which commonly investigates safety, dosage and preliminary signs of activity; clinical benefit is uncertain.

International patients can request assessment for potentially relevant trials, but access depends on the study protocol and local administrative requirements. Screening may consider tumour subtype, molecular findings, previous therapies, overall fitness and laboratory results. Residence, insurance, language and the ability to attend repeated visits may also require clarification. Ask for the study identifier, current recruitment status, consent information and any required screening procedures before travelling. An initial discussion does not guarantee enrolment.

Start by requesting a records-based review or advice on the appropriate referral route. Provide a concise treatment history and clarify whether the goal is a second opinion, standard treatment or trial assessment. Where possible, obtain a provisional clinical plan before booking travel, while recognising that an examination or repeat testing may change recommendations.

Plan for continuity of care as well as the initial visit. Agree who will manage urgent symptoms, treatment complications and prescriptions during and after the stay. Ask how reports will reach the home oncology team and whether follow-up can be shared. Medical suitability, financial approval and travel feasibility should all be confirmed separately.

Contact details below come from the hospital's own published international patient information.

Location: Lyon, France

Email: patients.international@lyon.unicancer.fr

Phone: +33 4 78 78 28 28

Website: https://www.centreleonberard.fr

Languages supported: French, English, Arabic

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.